Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sutent®/Sunitinib Clear all
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

NCT00474994
View directory record Official record
Conditions
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

NCT01984242
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
25
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 17, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT00906360
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy, cetuximab
Drug · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 17, 2026, 10:03 AM EDT
Active, not recruiting Phase 3 Interventional

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673
View directory record Official record
Conditions
Non-Clear Cell Renal Cell Carcinoma
Interventions
XL092, Nivolumab, Sunitinib Malate
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Duarte, California • Newport Beach, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

NCT00444314
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Panzem® NCD, Sunitinib Malate
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 17, 2026, 10:03 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

NCT00522249
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pegylated Alfa Interferon, sunitinib, erlotinib
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

NCT00378911
View directory record Official record
Conditions
Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma
Interventions
sunitinib malate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 17, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy

NCT00402415
View directory record Official record
Conditions
Tumors
Interventions
Sunitinib malate, Rapamycin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib

NCT00471328
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 17, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions
Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Olaparib, Nivolumab and Ipilimumab, Abemaciclib, Talazoparib, Atezolizumab and Talazoparib, Tucatinib plus Trastuzumab Subcutaneous (SC), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
12 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
174
States / cities
Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Alternating Sunitinib and Temsirolimus

NCT01517243
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Sunitinib, Temsirolimus
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

NCT02401815
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
CGT9486, Pexidartinib, Sunitinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Results available

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

NCT00694096
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Sunitinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Sep 17, 2026, 10:03 AM EDT
Terminated Phase 3 Interventional Results available

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

NCT00699374
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
sunitinib malate, sorafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
35
States / cities
Fountain Valley, California • La Jolla, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT00451048
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
Interventions
sunitinib malate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

NCT01472081
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Pazopanib, Sunitinib, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
10
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 17, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

NCT01402817
View directory record Official record
Conditions
Neurofibromatosis, NF1, Plexiform Neurofibromas
Interventions
Sutent®/Sunitinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 17, 2026, 10:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

NCT03729245
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
bempegaldesleukin, sunitinib, nivolumab, cabozantinib
Biological · Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Anchorage, Alaska • Goodyear, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

NCT00495872
View directory record Official record
Conditions
Solid Tumors
Interventions
Dasatinib, Erlotinib, Lapatinib, Lenalidomide, Sorafenib, Sunitinib, Valproic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Sep 17, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Sutent + Taxol for Advanced Esophageal Cancer

NCT00730353
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Sunitinib malate, Paclitaxel
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Chicago, Illinois • Galesburg, Illinois • Bloomington, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 17, 2026, 10:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

NCT00905021
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Exemestane, Sutent
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 17, 2026, 10:03 AM EDT